A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia
about
Advances in antibiotic therapy in the critically illCharacteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientPseudomonas aeruginosa ventilator-associated pneumonia managementCeftobiprole for the treatment of pneumonia: a European perspectivePharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsCurrent and Future Considerations for the Treatment of Hospital-Acquired PneumoniaCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaThe intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.Antibiotics for ventilator-associated pneumonia.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy.Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.The time-dependent "cure-death" model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogens.Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?Emerging drugs for nosocomial pneumonia.Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.New horizons in hospital acquired pneumonia in older people.[New antibiotics - standstill or progress].Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.[Severe pneumonia in the intensive care unit].[New antibacterial agents on the market and in the pipeline].Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.Assessing Noninferiority in Treatment Trials for Severe Infectious Diseases: an Extension to the Entire Follow-Up Period Using a Cure-Death Multistate Model.Editorial Commentary: Antimicrobial De-escalation: What's in a Name?Linezolid: a review of its properties, function, and use in critical care.Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015
P2860
Q26749328-AE8DDE43-1D1D-42C3-A358-CCB1E45EEFF7Q26752680-F32584BA-9083-4BBA-9F68-1B2A101F5990Q26768365-AE57386E-BF5D-472B-85DD-3B5B8C3F743EQ26796463-652EBFAA-C9C2-4B08-94DC-4C47B84405ECQ28066877-0C01FBD4-1011-4A0E-8A44-4747442E016CQ28071882-5CE6BC48-3ABE-4421-9E36-C8A7AECF4037Q28085517-DA510AA8-552D-4663-8DE0-D157A4AB49B9Q30238578-2E6F06D6-0B61-40EE-B3E7-5857E1666AAAQ30243877-BA84335E-E33C-403B-8302-91834491AB93Q33429168-CB262A00-0AC9-425B-812A-A4D033FF4301Q33822682-152FE621-1118-4AB2-8D3C-44381A971C35Q34433342-E56546BB-99DC-40A9-8B05-26855E4C9434Q35542062-57FEF067-A052-4E2B-82BA-D9CE305AEB21Q36078359-5D886AFE-B420-4364-BE4A-571E47373896Q36355345-FF8EE291-9066-4D4C-9C46-17787BC9AF18Q36489501-4A407822-7B97-4A3C-B0B5-7770C2C46BBDQ38462842-E8856743-FE42-454B-8E9B-45E69D9AE7F4Q38468392-A1EFF00B-DD42-404A-B559-6A7E9394967EQ38672879-D49091DF-105A-4CDA-A2FB-9E1A21885E85Q38835029-49DC3C56-3144-402C-B47A-F89A8E003356Q38878167-E8AFFCC4-0770-4484-BE17-3E8DD67338F7Q39164183-6CA8803D-190D-4ABE-AB64-5B51EF0471EFQ40279983-02E2AFE8-C729-4C2C-8AFC-2E4EDA111C08Q40289701-57907215-0603-4C42-B75B-31655EDE98CAQ40422166-1A0CE259-E099-4518-B10F-78C22C37172EQ40763182-8871ABD1-51B7-43DA-A336-B8AA3980A6E9Q40948209-64525A93-D476-4D55-B012-0B5F37C1DCEBQ41695620-51DE1566-D44C-4040-9728-25BA9D662379Q47634145-70A645A3-850E-4CDB-8F24-1B7F8B819857Q48143379-36BD24F4-3F15-451A-A211-CEB9E7D15BA2Q53804008-2A845867-53C6-4B32-90E2-2DC68F5CE750Q55368160-A8141778-196E-44BE-A792-B5AFE03E773CQ56835140-F622D3A3-A845-4C16-B971-2FDB79440E34
P2860
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@ast
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@en
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@nl
type
label
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@ast
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@en
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@nl
prefLabel
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@ast
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@en
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@nl
P2093
P2860
P356
P1476
A phase 3 randomized double-bl ...... of hospital-acquired pneumonia
@en
P2093
Alejandro H Rodriguez
Alejandro S Sánchez
Alex J Pareigis
Marc Engelhardt
Mikaël Saulay
Samir S Awad
Yin-Ching Chuang
Zsuszanna Marjanek
P2860
P356
10.1093/CID/CIU219
P407
P577
2014-04-09T00:00:00Z